Year: 2021

16 December 2021 PRESS RELEASE Ad hoc announcement pursuant to Art. 53 listing rules: GAM International Management Limited reaches settlement with the FCA GAM Holding AG’s UK subsidiary, GAM International Management Limited (GIML), has reached a settlement with the Financial Conduct Authority (FCA). The FCA opened the investigation into GIML following the suspension of an investment director on 31st July 2018. This settlement concerns the operation of GIML’s conflicts of interest framework between November 2014 and October 2017 and conflicts of interest arising out of three specific investments made by the Absolute Return Bond Fund (ARBF) team between October 2016 and March 2018. GIML has fully cooperated with the FCA’s investigation, and this brings their investigation into GIML to a close. There are no other regulatory investigations...

KEYNOTE-B79 Phase 1b trial will evaluate CYAD-101 and KEYTRUDA® (pembrolizumab) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) ASCO-GI conference abstract accepted that highlights KEYNOTE-B79 clinical trial designMONT-SAINT-GUIBERT, Belgium, Dec. 16, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“the Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced the first patient was dosed in the KEYNOTE-B79 Phase 1b trial (NCT04991948). The KEYNOTE-B79 trial is part of a collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, through a subsidiary. The trial will evaluate the Company’s lead developmental candidate, its TCR Inhibitory...

On December 15th, 2021 JSC Olainfarm has received announcement on substantial participation from AS AB CITY. According to the announcement share of voting rights is 96.12%. Other persons that belong to controlled company’s chain have 23.15% (SIA FARMA FUND) of voting rights. The received announcement (in Latvian) is attached.Additional information:  Jānis LeimanisJSC Olainfarm Member of the Management BoardTel. +371 29269424E-pasts: janis.leimanis@olainfarm.comAttachmentVeidlapa_lidz.AS AB CITY_AS Olainfarm_15.12.2021-signed

VANCOUVER, British Columbia, Dec. 15, 2021 (GLOBE NEWSWIRE) — Allied Hotel Properties Inc. (TSX-V: AHP) (the “Company” or “Allied”) is pleased to announce the voting results from Monday’s special meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares of the Company (the “Shares”). At the Meeting, the Shareholders were asked to consider and, if deemed advisable, pass a special resolution (the “Arrangement Resolution”) approving a statutory plan of arrangement with Allied Holdings Ltd. (“Allied Holdings”) pursuant to Part 9, Division 5 of the Business Corporations Act (British Columbia) (the “Arrangement”). Pursuant to the Arrangement, the Company will redeem all of the issued and outstanding Shares (other than those Shares currently owned by Allied Holdings) (the “Minority Shares”) by paying $0.28 in cash for...

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) — Spree Acquisition Corp. 1 Limited (the “Company”) announced today that it priced its initial public offering of 17,500,000 units at $10.00 per unit. The units are expected to be listed on the New York Stock Exchange (“NYSE”) and trade under the symbol “SHAPU” beginning on December 16, 2021. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and redeemable warrants are expected to be listed on the NYSE under the symbols “SHAP” and “SHAPW,” respectively. The Company is a blank check company formed for the purpose of effecting a merger, amalgamation,...

PHILADELPHIA, PA, Dec. 15, 2021 (GLOBE NEWSWIRE) — FTAC Emerald Acquisition Corp. (NASDAQ: EMLDU) (the “Company”), a blank-check company led by Betsy Z. Cohen, as Chairman of the Board, Mark Tercek, as Vice-Chairman of the Board, and Bracebridge H. Young, Jr., as President and Chief Executive Officer, formed for the purpose of acquiring or merging with one or more businesses, today announced the pricing of its initial public offering of 22,000,000 units at a price of $10.00 per unit, for gross proceeds to the Company of $220,000,000. The Company’s units will be listed on the Nasdaq Global Market (NASDAQ) under the symbol “EMLDU” and will begin trading on December 16, 2021. Each unit issued in the offering consists of one share of Class A common stock of the Company and one-half of one redeemable warrant, each...

PLANO, Texas, Dec. 15, 2021 (GLOBE NEWSWIRE) — (NYSE: GRBK) Green Brick Partners, Inc., (the “Company”), today announced it has commenced an underwritten registered public offering of 2,000,000 depositary shares, each representing a 1/1000th fractional interest in a share of the Company’s Series A Cumulative Perpetual Preferred Stock, with a liquidation preference of $25.00 per depositary share, to raise anticipated gross proceeds of $50.0 million before deducting transaction expenses, subject to market and certain other conditions.  The Company expects to grant the underwriters a 30-day option to purchase additional depositary shares in connection with the offering. The Company expects to use the net proceeds of this offering for general corporate and working capital purposes, which may include expansion of the business, repurchases...

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received feedback from the US Food & Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) on the Phase 3 program of rexlemestrocel-L in patients with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to available therapies, including opioids. Mesoblast plans to conduct an additional US Phase 3 trial which may support submissions for potential approval in both the US and EU. The trial will include at least 20% of subjects from the EU to support global submission plans. Following review of the completed Phase 3 trial data, OTAT agreed with Mesoblast’s proposal for pain reduction at 12 months...

PEWAUKEE, Wis., Dec. 15, 2021 (GLOBE NEWSWIRE) — Westbury Bancorp, Inc. (OTCQX: WBBW), the holding company (the “Company”) for Westbury Bank (the “Bank”), today announced net income of $2.3 million, or $0.90 per common share for the three months ended September 30, 2021, and $9.5 million, or $3.70 per common share, for the year ended September 30, 2021, compared to net income of $1.9 million, or $0.76 per common share for the three months ended September 30, 2020, and net income of $7.2 million, or $2.59 per common share, for the year ended September 30, 2020. About Westbury Bancorp, Inc. Westbury Bancorp, Inc. is the holding company for Westbury Bank. The Company’s common shares are traded on OTCQX under the symbol “WBBW”. Westbury Bank is an independent community bank primarily serving communities in Washington and Waukesha...